Juan C Carril
Overview
Explore the profile of Juan C Carril including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
212
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cacabelos R, Carril J, Corzo L, Pego R, Cacabelos N, Alcaraz M, et al.
Pharmacogenomics
. 2023 Jan;
24(1):27-57.
PMID: 36628952
Anxiety and depression coexist with cognitive impairment in Alzheimer's disease along with other concomitant disorders (>60%), which require multipurpose treatments. Polypharmaceutical regimens cause drug-drug interactions and adverse drug reactions, potentially...
2.
Cacabelos R, Naidoo V, Martinez-Iglesias O, Corzo L, Cacabelos N, Pego R, et al.
Methods Mol Biol
. 2022 Sep;
2547:275-387.
PMID: 36068470
Alzheimer's disease (AD) is a priority health problem in developed countries with a high cost to society. Approximately 20% of direct costs are associated with pharmacological treatment. Over 90% of...
3.
Cacabelos R, Naidoo V, Martinez-Iglesias O, Corzo L, Cacabelos N, Pego R, et al.
Life (Basel)
. 2022 Mar;
12(3).
PMID: 35330211
Alzheimer’s disease (AD) is a priority health problem with a high cost to society and a large consumption of medical and social resources. The management of AD patients is complex...
4.
Cacabelos R, Naidoo V, Corzo L, Cacabelos N, Carril J
Int J Mol Sci
. 2021 Dec;
22(24).
PMID: 34948113
Adverse drug reactions (ADRs) rank as one of the top 10 leading causes of death and illness in developed countries. ADRs show differential features depending upon genotype, age, sex, race,...
5.
Cacabelos R, Carrera I, Martinez O, Alejo R, Fernandez-Novoa L, Cacabelos P, et al.
Med Res Rev
. 2021 Jun;
41(5):2841-2886.
PMID: 34106485
Atremorine is a novel bioproduct obtained by nondenaturing biotechnological processes from a genetic species of Vicia faba. Atremorine is a potent dopamine (DA) enhancer with powerful effects on the neuronal...
6.
Cacabelos R, Carril J, Corzo L, Fernandez-Novoa L, Pego R, Cacabelos N, et al.
Pharmaceuticals (Basel)
. 2021 Apr;
14(4).
PMID: 33920985
Background: Mood disorders represent a risk factor for dementia and are present in over 60% of cases with Alzheimer's disease (AD). More than 80% variability in drug pharmacokinetics and pharmacodynamics...
7.
Cacabelos R, Carrera I, Martinez O, Naidoo V, Cacabelos N, Aliev G, et al.
Drug Dev Res
. 2021 Jan;
82(5):695-706.
PMID: 33458869
Atremorine is a potent dopamine (DA) enhancer obtained by nondenaturing biotechnological processes from a genetic species of Vicia faba. Atremorine affects the neuronal dopaminergic system by acting as a neuroprotective...
8.
Cacabelos R, Carrera I, Alejo R, Fernandez-Novoa L, Cacabelos P, Corzo L, et al.
Planta Med
. 2019 Sep;
85(17):1351-1362.
PMID: 31559607
Atremorine is a novel bioproduct with neuroprotective effects on dopaminergic neurons and a natural L-DOPA donor in Parkinson's disease (PD). In the present study, we show the effects of a...
9.
Cacabelos R, Cacabelos N, Carril J
Expert Rev Clin Pharmacol
. 2019 Mar;
12(5):407-442.
PMID: 30916581
Adverse drug reactions (ADRs) are a major health concern worldwide. There are multiple causes of ADRs, some of which are preventable. Pharmacogenomics accounts for ≈80% variability in drug efficacy and...
10.
Cacabelos R, Carril J, Cacabelos N, Kazantsev A, Vostrov A, Corzo L, et al.
Int J Mol Sci
. 2019 Mar;
20(5).
PMID: 30871086
Sirtuins (SIRT1-7) are NAD⁺-dependent protein deacetylases/ADP ribosyltransferases with important roles in chromatin silencing, cell cycle regulation, cellular differentiation, cellular stress response, metabolism and aging. Sirtuins are components of the epigenetic...